Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
84 Cards in this Set
- Front
- Back
possible mechanisms fo arrhythmia?
|
abnormal impulse generation
altered impulse conduction (re-entry) |
|
types of abnormal impulse generation?
|
increased automaticity
afterdepolarizations |
|
early afterdepolarization?
|
arises from plateau prior to full repolarization;
exacerbated at slow rates; long QT-related arrhythmias such as torsades de pointes |
|
delayed afterdepolarization?
|
arises from resting potential;
thought to be related to Ca in cell; exacerbated by rapid rates; some digitalis-induced arrhythmias |
|
general properties of antiarrhythmic drugs?
|
may increase refractory period or slow conduction;
low therapeutic index (sometimes serious adverse effects even at therapeutic ranges); proarrhythmic effects (worsen current or induce new arrhythmias) |
|
class I drugs?
|
quinidine
procainamide disopyramide lidocaine mexiletine propafenone flecainide |
|
class II drugs?
|
β blockers
|
|
class III drugs?
|
bretylium
sotalol amiodarone ibutilide dofetilide |
|
class IV drugs?
|
verapamil
diltiazem |
|
misc antiarrhythmic drug?
|
adenosine
|
|
examples of use of quinidine?
|
atrial fibrillation and flutter
serious ventricular arrhythmias |
|
electrophysiologic actions of quinidine?
|
blocks Na and K channels
alpha blockade antivagal effects |
|
effect of blocking Na channels?
|
decrease conduction velocity
|
|
effect of blocking K channels?
|
increase action potential duration (ERF);
associated with increased QT interval; can be associated with torsades de pointes and early afterdepolarization |
|
antivagal effect of quinidine?
|
may cause paradoxical increase in ventricular rate in patients with atrial flutter as AV node is more likely to transmit more impulses to ventricles
|
|
quinidine pharmacokinetics?
|
well absorbed
hepatic metabolism 20% excreted unchanged in urine |
|
adverse effects of quinidine?
|
cardiac (high risk of arrhythmias)
GI (diarrhea) cinchonism (headache, tinnitus) hypersensitivity (thrombocytopenia, hepatotoxicity) |
|
thrombocytopenia as adverse effect?
|
quinidine
|
|
quinidine + digoxin interaction?
|
increased plasma digoxin level
|
|
quinidine + phenytoin or phenobarbital interaction?
|
decreased quinidine level
|
|
quinidine + CYP2D6 interaction?
|
quinidine can inhibit CYP2D6
|
|
which P450 can quinidine inhibit?
|
CYP2D6
|
|
example of use of procainamide?
|
serious ventricular arrhythmias
|
|
procainamide metabolism and consequence?
|
acetylation;
NAPA is active metabolite; greater incidence of drug induced lupus and (+)ANA with slow acetylators |
|
procainamide metabolite and its effect?
|
N-acetylprocainamide (NAPA): increases AP duration, need to monitor both
|
|
electrophysiologic actions of procainamide?
|
Na and K channel blocker
|
|
adverse effects of procainamide?
|
cardiac
hypotension nausea drug induced lupus agranulocytosis |
|
agranulocytosis?
|
procainamide
|
|
example of use of disopyramide?
|
serious ventricular arrhythmias
|
|
disopyramide actions?
|
block Na and K channels
anticholinergic negative inotropic effect |
|
disopyramide adverse effects?
|
cardiovascular
anticholinergic |
|
lidocaine example of use?
|
acute treatment of ventricular arrhythmias
|
|
lidocaine electrophysiologic action?
|
decreased conduction in depolarized cells (eg ischemia);
block Na channels |
|
lidocaine administration?
|
IV due to extensive first pass metabolism when give po;
clearance decreased by liver disease, heart failure, propranolol (due to decreased liver blood flow) |
|
lidocaine adverse effects?
|
neurologic: tremor, altered consciousness, seizures;
least cardiotoxic Na channel blocker |
|
one of the least cardiotoxic of the currently used sodium channel blockers?
|
lidocaine
|
|
mexiletine?
|
oral lidocaine-like drug
block Na channels |
|
examples of use of mexiletine?
|
serious ventricular arrhythmias
orally effective lidocaine analog |
|
flecainide examples of use?
|
maintenance of sinus rhythm in certain supraventricular arrhythmias in patients without structural heart disease
|
|
flecainide electrophysiologic effects?
|
blocks Na and K channels although does not prolong the AP;
decreased contractility |
|
adverse effects of flecainide?
|
blurred vision
can worsen heart failure cause or exacerbate potentially fatal arrhythmias can also cause heart block |
|
Cardiac Arrhythmia Suppression Trial?
|
showed increased mortality in post-MI patients with premature ventricular contractions treated with flecainide
|
|
propafenone use?
|
supraventricular arrhythmias
|
|
propafenone effects?
|
blocks Na channels
β blocking activity |
|
propranolol example of use?
|
atrial fibrillation
|
|
electrophysiologic effects of propranolol?
|
β blockade
membrane stabilizing action |
|
amiodarone uses?
|
serious ventricular arrhythmias
also effective in certain supraventricular arrhythmias |
|
electrophysiologic effects of amiodarone?
|
blocks K, Na, Ca channels
antiadrenergic anticholinergic |
|
amiodarone effect?
|
increase AP duration
vasodilation |
|
amiodarone pharmacokinetics?
|
long terminal half-life (weeks)
|
|
amiodarone adverse effects?
|
decreased heart rate
pulmonary fibrosis thyroid dysfunction corneal microdeposits photosensitivity, blue-gray discoloration hepatotoxicity neuro can worsen arrhythmias inhibits p450 hypotension |
|
pulmonary fibrosis?
|
amiodarone
|
|
corneal microdeposits in virtually all?
|
amiodarone
|
|
photosensitivity and blue-gray discoloration?
|
amiodarone
|
|
torsades de pointes relatively uncommon despite QT prolongation?
|
amiodarone
|
|
drug interactions with amiodarone?
|
decreases elimination of several drugs (warfarin, digoxin)
|
|
amiodarone structure?
|
contain two iodine that are thought to cause thyroid dysfunction
|
|
dronedarone example of use?
|
atrial fibrillation or atrial flutter in certain patients
|
|
adverse effects of dronedarone?
|
diarrhea, n/v
QT prolongation fetal harm possible drug interactions |
|
contraindications for dronedarone?
|
NYHA class IV HF or NYHA class II-III HF with recent decompensation requiring hospitalization or referral to a specialized heart failure clinic;
pregnancy |
|
sotalol examples of use?
|
serious ventricular arrhythmias
maintenance of sinus rhythm in patients with symptomatic AFIB/AFL who are currently in sinus rhythm |
|
electrophysiologic effects of sotalol?
|
increased AP duration
increase QT interval decreased conduction velocity in AV node decreased refractoriness of AV node |
|
sotalol action?
|
block K channel
β blocker racemic mixture |
|
adverse effects of sotalol?
|
adverse effects of β blockade
torsades de pointes (proarrhythmic) |
|
dofetilide examples of use?
|
maintenance of normal sinus rhythm in patients with atrial fibrillation;
conversion of atrial fibrillation |
|
electrophysiologic effects of dofetilide?
|
increases AP duration
block K rectifying channel increased QT interval |
|
excretion of dofetilide?
|
secreted by organic cation system
|
|
dofetilide administration?
|
oral
|
|
adverse effects of dofetilide?
|
torsades de pointes
necessary education program for hospitals and prescribers drug interactions |
|
ibutilide example of use?
|
rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm
|
|
ibutilide electrophysiologic effects?
|
increase AP duration
block rectifying K channel increase inward Na current increase QT interval |
|
ibutilide pharmacokinetics?
|
IV
hepatic metabolism |
|
ibutilide adverse effects?
|
torsades de pointes
education program for patients |
|
verapamil examples of use?
|
certain supraventricular arrhythmias
|
|
verapamil actions?
|
blocks activated and inactivated Ca channels;
decreases conduction velocity and increases ERP of AV node; vasodilation; decreased myocardial contractility |
|
verapamil adverse effects?
|
hypotension
depressed contractility heart block etc |
|
diltiazem examples of use?
|
certain supraventricular arrhythmias
|
|
adenosine examples of use?
|
conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm
|
|
adenosine action?
|
acts on adenosine receptors
slow AV conduction increased RP in AV node |
|
adenosine pharmacokinetics?
|
given by rapid IV administration
half life <10 sec |
|
adenosine adverse effects?
|
typically transient (short t1/2)
flushing headache hypotension arrhythmias heart block asystole dyspnea, chest discomfort drug interactions |
|
asystole?
|
adenosine
|
|
methylxanthine + adenosine interaction?
|
inhibit adenosine receptors to reduce drug effect (caffeine)
|
|
dipyridamole + adenosine interaction?
|
adenosine uptake inhibitor to increase effect
|